Medicus Appoints Andrew Smith As COO; Expands BCC Trials And Eyes Prostate Cancer Market With Antev Deal

Medicus Pharma Ltd. has appointed Andrew Smith as its new Chief Operating Officer. Smith brings over 30 years of leadership in asset management and financial operations, having served most recently as CEO of SR Asset Management until its 2024 sale. Prior to that, he held key executive roles at Aberdeen Asset Management, including Co-Head of Americas and COO. Smith also served as CFO and CCO for various Aberdeen divisions and currently holds board and advisory roles with HazelTree Fund Services and Code Registry.

“We are delighted to welcome Andrew to the leadership team. Andrew’s experience and expertise is very relevant and timely, as we expand our business and clinical development operations with active engagements on three continents,” stated Dr. Raza Bokhari, Executive Chairman and CEO. 

The company’s Phase 2 clinical trial of D-MNA (SKNJCT-003) for non-invasive treatment of basal cell carcinoma (BCC) has now randomized over 50 of the planned 90 patients. This study, running across nine U.S. sites since August 2024, showed promising early results in March 2025, with over 60% clinical clearance in interim findings. Following these results, the trial was expanded to include 90 participants, with additional clinical sites opening in Europe.

Medicus is also progressing its SKNJCT-004 study in the UAE, targeting 36 patients across four prominent hospitals, including Cleveland Clinic Abu Dhabi and Sheikh Shakbout Medical City. The trial is being managed by UAE-based CRO Insights Research Organization and Solutions (IROS), part of M42. In parallel, Medicus signed a binding letter of intent in April 2025 to acquire UK-based Antev Ltd., which is developing Teverelix, a next-generation GnRH antagonist for advanced prostate cancer and acute urinary retention linked to an enlarged prostate.